AUROPHARMA — Aurobindo Pharma Balance Sheet
0.000.00%
Last trade - 00:00
- IN₹636.94bn
- IN₹629.12bn
- IN₹248.55bn
- 87
- 28
- 99
- 87
C2019 March 31st | R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 19,529 | 28,341 | 56,212 | 45,576 | 62,327 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 61,219 | 58,660 | 50,548 | 58,830 | 66,871 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 153,323 | 164,125 | 198,235 | 181,227 | 215,457 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 70,356 | 81,166 | 93,155 | 106,660 | 124,918 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 264,544 | 289,277 | 338,540 | 339,217 | 398,900 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 120,206 | 113,846 | 106,652 | 81,560 | 114,938 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 125,636 | 121,031 | 119,241 | 93,457 | 130,501 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 138,908 | 168,247 | 219,299 | 245,760 | 268,399 |
Total Liabilities & Shareholders' Equity | 264,544 | 289,277 | 338,540 | 339,217 | 398,900 |
Total Common Shares Outstanding |